🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "significant breakthrough" in the battle against drug-resistant strains of the bacteria, according to scientists.

An International Health Concern

The sexually transmitted infection are increasing worldwide, with data suggesting in excess of 82 million infections annually. Especially elevated rates are seen in the African continent and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely development in the face of rising global incidence, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Medical experts are deeply concerned about the rise in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance showed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, also known as Nuzolvence, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists believe that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in the same week. This treatment, which is also used to treat urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This authorization signifies a significant shift in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Data and Worldwide Availability

According to findings detailed in a prominent scientific publication, the new drug eradicated over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which involves a dual-drug approach. The research enrolled hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the authority to license and sell the drug in many regions with limited resources.

Doctors on the front lines have expressed optimism. The availability of a single-dose, oral treatment like this is seen as a "game-changer" for gonorrhoea control. This is viewed as vital to alleviate the strain of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.